2.309

1.22% 0.039

Rapt Therapeutics Inc (RAPT)

Overview News Price History Option Chain Financials Discussions Forecast

Rapt Therapeutics Inc stock is traded at $2.309, with a volume of 132.93K. It is up +1.22% in the last 24 hours and up +14.88% over the past month. RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Previous Close:

$2.27

Open:

$2.26

24h Volume:

132.93K

Relative Volume:

0.51

Market Cap:

$80.98M

Revenue:

$3.25M

Net Income/Loss:

$-116.80M

P/E Ratio:

-0.8584

EPS:

-2.69

Net Cash Flow:

$-98.17M

1W Performance:

+14.88%

1M Performance:

+14.88%

6M Performance:

-72.42%

1Y Performance:

-85.18%

1-Day Range:

$2.18

$2.36

1-Week Range:

$1.98

$2.50

52-Week Range:

$1.64

$27.35

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name

Rapt Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(650) 489-9000

Address

561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA

Employee

122

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RAPT's Discussions on Twitter

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-14-24	Downgrade	Wolfe Research	Outperform → Peer Perform
May-10-24	Downgrade	Barclays	Overweight → Equal Weight
May-10-24	Downgrade	Guggenheim	Buy → Neutral
Feb-22-24	Downgrade	UBS	Buy → Neutral
Feb-21-24	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-21-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-21-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-20-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-16-24	Initiated	Evercore ISI	Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform
Sep-14-23	Initiated	Berenberg	Buy
Aug-09-23	Initiated	Stifel	Buy
Jun-15-23	Initiated	Barclays	Overweight
Jan-04-23	Initiated	Guggenheim	Buy
Dec-01-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	CapitalOne	Overweight
May-24-22	Resumed	Cantor Fitzgerald	Overweight
Dec-09-21	Initiated	JP Morgan	Overweight
Aug-12-21	Initiated	SVB Leerink	Outperform
Jun-21-21	Initiated	Piper Sandler	Overweight
Jun-01-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Cantor Fitzgerald	Overweight
Apr-13-20	Initiated	ROTH Capital	Buy
Nov-25-19	Initiated	BMO Capital Markets	Outperform
Nov-25-19	Initiated	UBS	Buy
Nov-25-19	Initiated	Wells Fargo	Outperform

View All

Rapt Therapeutics Inc Stock (RAPT) Latest News

03:30 AM

Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com

03:30 AM

Oct 22, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia

Oct 22, 2024

Oct 21, 2024

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat

Oct 21, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com

Oct 21, 2024

Oct 10, 2024

RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com

Oct 10, 2024

Oct 04, 2024

Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat

Oct 04, 2024

Oct 03, 2024